Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30354091 | 1.00 | HTR3A (0.50) | HTR3AALDH1A1KDM4ESMN1; SMN2PDE3B | |
| SCHEMBL28129923 | 0.84 | BACE1 (0.54) | HTR3AALDH1A1KDM4ESMN1; SMN2DYRK1A | |
| SCHEMBL29918270 | 0.79 | HTR3A (0.39) | HTR3AALDH1A1KDM4ESMN1; SMN2PDE3B | |
| SCHEMBL1570789 | 0.79 | HTT (0.49) | HTR3AALDH1A1KDM4ESMN1; SMN2NOS1 | |
| SCHEMBL30718860 | 0.79 | ALDH1A1 (0.50) | HTR3AALDH1A1KDM4ESMN1; SMN2PDE3B | |
| SCHEMBL2130969 | 0.79 | PIK3CG (0.53) | HTR3AKDM4ENR4A2DYRK1APIK3CG | |
| SCHEMBL15888390 | 0.79 | HTR3A (0.51) | HTR3AALDH1A1KDM4EPDE3BPDE3A | |
| SCHEMBL446874 | 0.79 | KDM4E (0.46) | HTR3AALDH1A1KDM4ESMN1; SMN2PDE3B | |
| SCHEMBL1571191 | 0.79 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2PDE3BPDE3A | |
| SCHEMBL13362651 | 0.79 | KDM4E (0.46) | HTR3AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092065-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| CN-115335050-B | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023133217-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133217-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-116023372-A | Compound of benzoxazole linkage electricity-absorbing segment and electron transport material | 烟台显华化工科技有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-11447493-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. | 2022-09-20 | — | — | US | disclosed |
| EP-3787629-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210053969-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053969-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-02-25 | — | — | US | disclosed |
| CN-105732591-B | Substituted diethylenediamine compound and its application method and purposes | 广东东阳光药业有限公司 | 2019-10-25 | — | — | CN | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| EP-0248554-B1 | HETEROCYCLIC COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-03 | — | — | EP | disclosed |
| US-4871387-A | Pyri(mi)dyl-oxy-and -thio-benzoic acid derivatives useful as herbicides and plant growth regulants | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-03 | — | — | US | disclosed |
| EP-0248554-A2 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-12-09 | — | — | EP | disclosed |
| EP-0226837-A2 | Pyri(mi)dyloxy and -thiobenzoic acid derivatives | BAYER AG (DE) | 1987-07-01 | — | — | EP | disclosed |
| US-4675047-A | MONOCOTYLEDON WEES | ICI AUSTRALIA LIMITED, 1 NICHOLSON ST., MELBOURNE, VICTORIA, 3000, AUSTRALIA, A CORP. OF AUSTRALIA | 1987-06-23 | — | — | US | disclosed |
| EP-0044163-A2 | Quinazolinyloxy(amino)phenoxyalkane carboxylic acid derivatives, process for their synthesis, herbicidal compositions containing them and their use as herbicides | ICI AUSTRALIA LIMITED (AU) | 1982-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053969-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK2, CCNK, CDK1 | HTR3A 4251/4885ALDH1A1 3722/4885KDM4E 1278/4885 |
| US-11447493-B2 | Inhibitors of cyclin-dependent kinases | CDK2, CCNK, CDK1 | HTR3A 4251/4885ALDH1A1 3722/4885KDM4E 1278/4885 |
| US-20250092065-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SNRPA, SNRPB2, HNRNPAB | HTR3A 3524/4885ALDH1A1 2046/4885KDM4E 1965/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | HTR3A 983/4885ALDH1A1 526/4885KDM4E 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.